Methylphenidate

2020 Attention Deficit Hyperactivity Disorder - Pipeline Review, H1 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 11, 2020

The "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This latest Pharmaceutical and Healthcare disease pipeline guide Attention Deficit Hyperactivity Disorder - Pipeline Review, H1 2020, provides an overview of the Attention Deficit Hyperactivity Disorder (Central Nervous System) pipeline landscape.
  • The Pharmaceutical and Healthcare latest pipeline guide Attention Deficit Hyperactivity Disorder - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Attention Deficit Hyperactivity Disorder (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Attention Deficit Hyperactivity Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and features dormant and discontinued projects.

KemPharm Submits KP415 NDA to the FDA for the Treatment of ADHD

Retrieved on: 
Monday, March 2, 2020

KP415 is KemPharms product candidate for the treatment of attention deficit hyperactivity disorder (ADHD) which contains serdexmethylphenidate (SDX), KemPharms prodrug of d-methylphenidate (d-MPH).

Key Points: 
  • KP415 is KemPharms product candidate for the treatment of attention deficit hyperactivity disorder (ADHD) which contains serdexmethylphenidate (SDX), KemPharms prodrug of d-methylphenidate (d-MPH).
  • Submission of the KP415 NDA is a significant milestone for KemPharm as we seek FDA approval for our first ADHD product candidate based on our proprietary LAT prodrug technology, said Travis C. Mickle, Ph.D., President and CEO of KemPharm.
  • The license agreement provides that a regulatory milestone payment will be payable to KemPharm thirty (30) days following FDA acceptance of the KP415 NDA.
  • We look forward to working with the FDA as they complete their review of the KP415 NDA, Dr. Mickle concluded.

Pyramid Family Behavioral Healthcare Opens Second Freestanding Intensive Mental Health Outpatient Treatment Program

Retrieved on: 
Thursday, February 20, 2020

SANDY SPRINGS, Ga., Feb. 20, 2020 /PRNewswire/ --Pyramid Family Behavioral Healthcare announced today it plans to open a second adult and adolescent intensive mental health outpatient and partial hospitalization behavioral health treatment program in Sandy Springs, Georgia in March 2020.

Key Points: 
  • SANDY SPRINGS, Ga., Feb. 20, 2020 /PRNewswire/ --Pyramid Family Behavioral Healthcare announced today it plans to open a second adult and adolescent intensive mental health outpatient and partial hospitalization behavioral health treatment program in Sandy Springs, Georgia in March 2020.
  • Pyramid Family Behavioral Healthcare will fulfill a need within the community for additional behavioral health programming, as part of the organization's overall mission to make mental health services more accessible and convenient.
  • This is Pyramid Family Behavioral Healthcare's second treatment program in Georgia.
  • Pyramid Family Behavioral Healthcare serves those who are suffering with mood and anxiety disorders, such as depression, bipolar disorder, anxiety disorders, ADHD, and other common behavioral health conditions.

Global Attention-Deficit/Hyperactivity Disorder (ADHD) Pipeline Overview 2020: Emerging Therapies, Unmet Needs, Product Profiles, Key Players

Retrieved on: 
Wednesday, February 19, 2020

Attention-Deficit/Hyperactivity Disorder (ADHD) Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Attention-deficit/hyperactivity disorder (ADHD) market.

Key Points: 
  • Attention-Deficit/Hyperactivity Disorder (ADHD) Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Attention-deficit/hyperactivity disorder (ADHD) market.
  • A detailed picture of the Attention-deficit/hyperactivity disorder (ADHD) pipeline landscape is provided, which includes the disease overview and Attention-deficit/hyperactivity disorder (ADHD) treatment guidelines.
  • The assessment part of the report embraces in-depth Attention-deficit/hyperactivity disorder (ADHD) commercial assessment and clinical assessment of the Attention-deficit/hyperactivity disorder (ADHD) pipeline products from the pre-clinical developmental phase to the marketed phase.
  • How many Attention-deficit/hyperactivity disorder (ADHD) emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Attention-deficit/hyperactivity disorder (ADHD)?

BrainsWay Announces Data from Feasibility Study of Deep Transcranial Magnetic Stimulation System in the treatment of Adults with ADHD

Retrieved on: 
Monday, February 10, 2020

Additional study of this non-invasive treatment approach in this population is warranted.

Key Points: 
  • Additional study of this non-invasive treatment approach in this population is warranted.
  • The study enrolled 75 adults, ages 18-60 years, with ADHD who had not previously received TMS.
  • This study adds to the growing body of clinical evidence demonstrating the potential clinical benefits of dTMS in the treatment of ADHD.
  • BrainsWay is engaged in the research, development and sales and marketing of a medical system for non-invasive treatment of common brain disorders.

APSARD and Tris Pharma Announce the Inaugural Tris Research Award in ADHD

Retrieved on: 
Friday, January 17, 2020

The award recognizes innovative research that facilitates a better understanding of the diagnosis, recognition and/or treatment of ADHD and related disorders.

Key Points: 
  • The award recognizes innovative research that facilitates a better understanding of the diagnosis, recognition and/or treatment of ADHD and related disorders.
  • APSARD is solely responsible for the management, decision making and oversight of this award.
  • APSARD is grateful to Tris for its commitment to a multi-year support of this award.
  • The Organization works to improve the quality of care for ADHD patients through shared research, best practices, evidence-based education and training.

Adlon Therapeutics L.P. and Purdue Pharma L.P. Will Present Data from Adhansia XR™ (methylphenidate HCl) Studies Examining Sleep Quality Outcomes, Functional Outcomes and Executive Functioning at the 2020 APSARD Annual Meeting

Retrieved on: 
Thursday, January 16, 2020

CNS stimulants, including Adhansia XR, other methylphenidate-containing products, and amphetamines have a high potential for abuse and dependence.

Key Points: 
  • CNS stimulants, including Adhansia XR, other methylphenidate-containing products, and amphetamines have a high potential for abuse and dependence.
  • The studies evaluated a maximum of 85 mg/day for adolescent patients and 100 mg/day for adult patients.
  • Patients were randomly assigned to either a daily dose of Adhansia XR (25, 45, 70 or 100 mg) or placebo.
  • Adhansia XR is contraindicated in patients with a known hypersensitivity to methylphenidate or other components of Adhansia XR.

Adlon Therapeutics L.P. and Purdue Pharma L.P. to Present Six Scientific Posters at the 2020 American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting

Retrieved on: 
Thursday, January 16, 2020

During dose-optimization, the most frequently reported treatment emergent adverse events (TEAEs) were headache (21.4%), decreased appetite (21.4%), and insomnia (16.1%).

Key Points: 
  • During dose-optimization, the most frequently reported treatment emergent adverse events (TEAEs) were headache (21.4%), decreased appetite (21.4%), and insomnia (16.1%).
  • As a research-driven organization, we continually strive to improve the understanding of our products across their lifecycle stages.
  • It is important for our current and future business goals to continue making medications like Adhansia XR available for appropriate patients.
  • Adlon Therapeutics L.P. is a biopharmaceutical company dedicated to developing and providing treatment options for Attention-Deficit/Hyperactivity Disorder (ADHD) and related disorders.

Akili Study of AKL-T01 With and Without Stimulant Medication in Children With ADHD Achieves Primary Efficacy Endpoint

Retrieved on: 
Wednesday, January 15, 2020

The children were separated into two groups: one with children on stimulant medications and one with children not taking ADHD medication.

Key Points: 
  • The children were separated into two groups: one with children on stimulant medications and one with children not taking ADHD medication.
  • The primary efficacy outcome of the study was change in IRS, a parent-reported clinician-administered ADHD impairment scale, after one month of treatment.
  • The magnitude of improvement in IRS throughout the study was similar for children independent of their ADHD medication use.
  • The STARS-ADHD Adjunctive study is the fifth clinical study evaluating AKL-T01 in children with ADHD.

American BriVision Initiates Phase II Part I Clinical Trial for ABV-1505 in Adult Attention-Deficit Hyperactivity Disorder (ADHD)

Retrieved on: 
Thursday, December 5, 2019

This trial is an open label, single-center, dose escalation study to be conducted in six adult ADHD patients.

Key Points: 
  • This trial is an open label, single-center, dose escalation study to be conducted in six adult ADHD patients.
  • The primary objective of this study is to determine the effective doses and treatment period of PDC-1421 in adult patients with ADHD.
  • The secondary objective is to evaluate the safety of PDC-1421 in patents receiving the drug at various dose levels.
  • A Phase II Part II study is expected to follow at the UCSF Medical Center, along with major medical centers in Taiwan, after and assuming successful completion of this Phase II Part I study.